Identifying biomarkers for CAR-T cell therapy in cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study analyzes patients receiving commercially available CAR-T therapies to identify cellular and molecular factors associated with treatment success and relapse. It aims to help tailor CAR-T approaches by understanding why some patients respond durably while others relapse. Data from adults treated at a university hospital in Lille will be used to link biomarkers with outcomes. The goal is to support more precise patient selection and improved durability of responses in hematologic malignancies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Male or female aged ≥ 18 years and able to provide informed consent
* Any indication,
* Commercially available CART therapies,
* Any conditioning.

Exclusion Criteria:

* Freedom privacy
* Absence of medical coverage
* Patients receiving CART or CAR-based cellular therapies which are not commercially available.

Where it's running

• chu de Lille
  Lille, France Recruiting
• Hop Claude Huriez Chu Lille
  Lille, France Terminated

Study contacts

• Principal investigator: Ibrahim Yakoub-Agha, MD,PhD — University Hospital, Lille
• Study coordinator: Ibrahim Yakoub-Agha, MD,PhD
• Email: ibrahim.yakoubagha@chru-lille.fr
• Phone: 0320445962

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• In Vivo CD19/CD20 CAR T-Cell Therapy for Relapsed or Refractory B-Cell Lymphoma

  This early-phase trial tests a one-time in vivo CAR T-cell therapy (SL1617) for people with relapsed or refractory B-cell lymphoma to see if it is safe and tolerable.

  Recruiting Phase 1 Chinese PLA General Hospital · Beijing · NCT07775508

• Seeing if DCog Short on an iPad can spot neurotoxicity in CAR-T patients

  This study tests whether a self-report iPad tool called DCog Short can help identify neurotoxicity in people receiving CAR-T cell therapy.

  Recruiting Beth Israel Deaconess Medical Center · Boston, Massachusetts · NCT07403812

• CD19‑CAR T‑cell consolidation after TCRαβ/CD19‑depleted haploidentical family donor transplant for relapsed/refractory CD19+ B‑cell leukemia and lymphoma

  This will try giving CD19‑targeted CAR T cells shortly after a partially matched family‑donor transplant to children and young adults (≤21) with relapsed or refractory CD19+ B‑cell leukemia or lymphoma to see if the approach is safe and feasible.

  Recruiting Phase 1 St. Jude Children's Research Hospital · Memphis, Tennessee · NCT07257419

• CD5 CAR T-cell therapy for relapsed or refractory T-cell lymphoma

  This trial tries CD5 CAR T-cell therapy, using either the patient's own cells or donor cells, and may bridge to stem-cell transplant for people 14–70 with relapsed or refractory T-cell lymphoma.

  Recruiting at 3 sites Phase 1/2 Beijing GoBroad Hospital · Beijing and 2 other locations · NCT07022964

• Glofitamab plus obinutuzumab for mantle cell lymphoma after CAR‑T

  This trial tests whether the antibody drug glofitamab given with obinutuzumab can shrink or control mantle cell lymphoma that returned or didn't respond after CD19 CAR‑T therapy in adults.

  Recruiting at 11 sites Phase 2 National Cancer Institute (NCI) · Duarte, California and 10 other locations · NCT07003295

• CD7 CAR T-Cell Therapy for T-Cell Lymphomas

  This study is testing a new CAR T-cell therapy for people with T-cell lymphomas that haven't responded to regular treatments to see if it is safe and effective.

  Recruiting at 4 sites Phase 1/2 Beijing GoBroad Hospital · Beijing, Beijing Municipality and 3 other locations · NCT06925464

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.